about
sameAs
Synthetic models of the active site of catechol oxidase: mechanistic studiesTuning the cytotoxic properties of new ruthenium(III) and ruthenium(II) complexes with a modified bis(arylimino)pyridine Schiff base ligand using bidentate pyridine-based ligands.Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential.New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.Combinatorial discovery of new asymmetric cis platinum anticancer complexes is made possible with solid-phase synthetic methods.Controlled copper-mediated chlorination of phenol rings under mild conditions.The new anticancer drug [(2R)-aminomethylpyrrolidine](1, 1-cyclobutanedicarboxylato)platinum(II) and its toxic S enantiomer do interact differently with nucleic acids.Dinuclear alkyldiamine platinum antitumor compounds: a structure-activity relationship study.Tuning the rotational behavior of lopsided heterocyclic nitrogen ligands (L) in octahedral cis-[Ru(bpy)2(L)2](PF6)2 complexes. A variable-temperature 1H NMR study.Monofunctionally trans-diammine platinum(II)-modified peptide nucleic acid oligomers: a new generation of potential antisense drugs.Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.Platinum(II) compounds with chelating ligands based on pyridine and pyrimidine: synthesis, characterizations, DFT calculations, cytotoxic assays and binding to a DNA model base.Accurate non-invasive image-based cytotoxicity assays for cultured cells.Unprecedented water addition to the α,β-unsaturated enone bond, mediated by the combination of carbonate and platinum(II).Bio-mimicking galactose oxidase and hemocyanin, two dioxygen-processing copper proteins.Anion binding involving pi-acidic heteroaromatic rings.New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.Putting anion-π interactions into perspective.Fast and slow versus strong and weak metal-DNA binding: consequences for anti-cancer activity.Coordination chemistry beyond Werner: interplay between hydrogen bonding and coordination.DNA cleavage and binding selectivity of a heterodinuclear Pt-Cu(3-Clip-Phen) complex.DNA cleavage and antitumour activity of platinum(II) and copper(II) compounds derived from 4-methyl-2-N-(2-pyridylmethyl)aminophenol: spectroscopic, electrochemical and biological investigation.Platinum(II)-based coordination compounds as nucleic acid labeling reagents: synthesis, reactivity, and applications in hybridization assays.2,6-Bis(2,6-diethylphenyliminomethyl)pyridine coordination compounds with cobalt(II), nickel(II), copper(II), and zinc(II): synthesis, spectroscopic characterization, X-ray study and in vitro cytotoxicity.Light-stable bis(norharmane)silver(I) compounds: synthesis, characterization and antiproliferative effects in cancer cells.Copper curcuminoids containing anthracene groups: fluorescent molecules with cytotoxic activity.Synthesis, single-crystal and solution structure analysis and in vitro cytotoxic activity of two novel complexes of ruthenium(II) with in situ formed flavanone-based ligands.Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part I. Synthesis, cytotoxicity, and cellular studies in A2780 human ovarian carcinoma cells.Mono- and dinuclear platinum(II) compounds with 5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine. Structure, cytotoxic activity and reaction with 5'-GMP.Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand.Chemical, structural and biological studies of cis-[Pt(3-Acpy)(2)Cl(2)].Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands.High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis.Synthesis, crystal structure, studies in solution and cytotoxicity of two new fluorescent platinum(II) compounds containing anthracene derivatives as a carrier ligand.Phenanthroline derivatives with improved selectivity as DNA-targeting anticancer or antimicrobial drugs.Structure, cytotoxicity, and DNA-cleavage properties of the complex [Cu(II)(pbt)Br2].Platinated copper(3-clip-phen) complexes as effective DNA-cleaving and cytotoxic agents.New approach for the preparation of efficient DNA cleaving agents: ditopic copper-platinum complexes based on 3-Clip-Phen and cisplatin.New antitumour active platinum compounds containing carboxylate ligands in trans geometry: synthesis, crystal structure and biological activity.The square-planar cytotoxic [Cu(II)(pyrimol)Cl] complex acts as an efficient DNA cleaver without reductant.
P50
Q28260475-EBCFC0B6-4620-4E12-9596-90E5B0A302A2Q30734495-FE05D8B0-4574-4DDE-A408-847E37EB1306Q30741785-12726E9B-AF30-4341-8CBA-8D7D5210DC5AQ30786502-2380BC13-B683-489E-BBEF-CE810E4BB537Q30795573-B7218C27-23BD-499B-B907-B7C71E82097FQ31112388-1A1397AF-DF86-4631-B518-AAFAE8588778Q31426910-BFE3BA7A-62F3-4114-9C14-6121F61EB170Q31916996-7B0E3DFC-629F-4713-959F-D4D4ACA3A930Q31994315-A5C7BCC9-D5E6-406A-9F06-505C6BD086AFQ33185292-E017A240-77C3-4072-973E-DEEFA29E11C4Q33345021-7A19E0C1-4EAD-4AB0-AA49-3580284F30FDQ33490871-ED3BA001-4F4F-4E56-96C5-64C6BE8C9327Q33610821-4F74D632-99D9-49AC-BE35-733CF431E7CAQ33705637-A78F610F-38A6-4BEB-BAF0-36301EA37700Q34372519-8DE4B88D-A4BD-4D19-9E59-2A704B5CA284Q34619828-FB75225F-BC1B-4C85-A982-BE4C665685F1Q34914365-146A2A28-2DF7-473E-8FAC-EDF7D25D17EEQ37934799-774C2A27-A43C-4E99-ADE2-B73E27386E51Q38001300-416F1D00-A5F6-4632-A336-ED5A241C21EAQ38035712-00A10276-2CE1-45E0-AEFD-E5DE16046A52Q38293573-743F86DD-CB88-451A-AE90-496469651F8EQ38347803-EF93D6A8-D26D-4645-AD1E-E90FE1B62D2FQ38352730-D20931CD-2DAF-423C-84D8-5D69B543F0C1Q38950579-DBD1C3ED-63FD-4721-995A-60FFE76528A9Q38973758-8195784E-ACC7-4DDB-AE2B-7C18B39B59C9Q39656089-7286CDD8-0B70-48FC-9CCA-5E703C6B2F62Q39657338-167461DB-E9AF-40F7-8445-3ED95A4192ADQ39681201-0F1AEB59-453A-4429-8077-E15CDFE5008BQ39761127-FCC5E2B4-9EB2-46A0-B456-3F053B57E9DAQ39794738-E957A374-DDF9-48A1-BCA1-F66B0E11BD99Q39820177-3B81C16D-2823-493B-A961-365E0E7D3EA8Q39870096-6362A9E2-EBDC-4D35-A060-34D4C7BB16E0Q39882018-4950DE98-CF9F-4621-9C76-E9DCA7F9F31EQ39922801-99BCDDEB-FC92-4E29-85DC-C18D1D8004B9Q39974452-3A934124-05F3-437F-A1CE-C8FAB565052CQ39993382-32376581-4E86-4607-B512-61B1C1B8BD23Q40010000-F455AC59-54E1-4AF6-8401-38894955EC7DQ40128943-ACBC3FFA-1F1A-4188-92C7-D3D62EF3BA2FQ40317205-A4E74A10-46AF-4EE6-B6BE-68428B7173EAQ40328670-1A37CB14-929F-4F5D-AC71-20467AE1B8B8
P50
description
Dutch chemist
@en
Dutch chemist
@en-ca
Dutch chemist
@en-gb
Hollandi keemik
@et
Nederlands scheikundige
@nl
chimist olandez
@ro
chimiste néerlandais
@fr
kimist holandez
@sq
químic neerlandès
@ca
químico neerlandés
@es
name
Jan Reedijk
@ast
Jan Reedijk
@ca
Jan Reedijk
@da
Jan Reedijk
@en
Jan Reedijk
@es
Jan Reedijk
@fr
Jan Reedijk
@nb
Jan Reedijk
@nl
Jan Reedijk
@nn
Jan Reedijk
@sl
type
label
Jan Reedijk
@ast
Jan Reedijk
@ca
Jan Reedijk
@da
Jan Reedijk
@en
Jan Reedijk
@es
Jan Reedijk
@fr
Jan Reedijk
@nb
Jan Reedijk
@nl
Jan Reedijk
@nn
Jan Reedijk
@sl
altLabel
J. Reedijk
@en
J. Reedijk
@nl
prefLabel
Jan Reedijk
@ast
Jan Reedijk
@ca
Jan Reedijk
@da
Jan Reedijk
@en
Jan Reedijk
@es
Jan Reedijk
@fr
Jan Reedijk
@nb
Jan Reedijk
@nl
Jan Reedijk
@nn
Jan Reedijk
@sl
P106
P108
P1006
P214
P244
P268
P269
P5361
P1006
P1153
7103016042
P1280
P1412
P19
P21
P213
0000 0001 0874 9399